Myriad Genetics, Inc. (LON:0K3W)
7.72
+0.35 (4.72%)
At close: Oct 13, 2025
Myriad Genetics Revenue
Myriad Genetics had revenue of $213.10M USD in the quarter ending June 30, 2025, with 0.76% growth. This brings the company's revenue in the last twelve months to $832.90M, up 3.83% year-over-year. In the year 2024, Myriad Genetics had annual revenue of $837.60M with 11.21% growth.
Revenue (ttm)
$832.90M
Revenue Growth
+3.83%
P/S Ratio
0.93
Revenue / Employee
$308.48K
Employees
2,700
Market Cap
562.62M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 837.60M | 84.40M | 11.21% |
Dec 31, 2023 | 753.20M | 74.80M | 11.03% |
Dec 31, 2022 | 678.40M | -12.20M | -1.77% |
Dec 31, 2021 | 690.60M | 133.60M | 23.99% |
Dec 31, 2020 | 557.00M | -81.60M | -12.78% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Myriad Genetics News
- 22 days ago - Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy - PRNewsWire
- 22 days ago - Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy - GlobeNewsWire
- 4 weeks ago - Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now? - Nasdaq
- 5 weeks ago - Myriad Genetics, Inc. (MYGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology | MYGN ... - GuruFocus
- 5 weeks ago - Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology - GlobeNewsWire
- 6 weeks ago - New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression - GlobeNewsWire
- 7 weeks ago - Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences - GlobeNewsWire